{"pmid":32272172,"title":"Does the COVID-19 outbreak identify a broader need for an urgent transformation of cancer clinical trials research?","text":["Does the COVID-19 outbreak identify a broader need for an urgent transformation of cancer clinical trials research?","Contemp Clin Trials","Borno, Hala T","Small, Eric J","32272172"],"journal":"Contemp Clin Trials","authors":["Borno, Hala T","Small, Eric J"],"date":"2020-04-10T11:00:00Z","year":2020,"_id":"32272172","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.cct.2020.105997","keywords":["COVID-19","Cancer disparities","Clinical trials"],"source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1663620083093602307,"score":7.9164424,"similar":[{"pmid":32234468,"title":"The epidemiology, diagnosis and treatment of COVID-19.","text":["The epidemiology, diagnosis and treatment of COVID-19.","In December 2019, the outbreak of the 2019 novel coronavirus disease (COVID-19) in China spread worldwide, becoming an emergency of major international concern. SARS-CoV-2 infection causes clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus. Human-to-human transmission has been described with incubation times between 2-14 days, facilitating its spread via droplets, contaminated hands or surfaces. Early diagnosis, quarantine, and supportive treatments are essential to cure patients. We therefore reviewed the literature on all available information about the epidemiology, diagnosis, isolation and treatments of COVID-19. Treatments, including antiviral agents, chloroquine and hydroxychloroquine, corticosteroids, antibodies, convalescent plasma transfusion and vaccines, will be discussed in this article. Additionally, registered trials about treatment were listed to develop approaches for the current urgent demand for therapy.","Int J Antimicrob Agents","Zhai, Pan","Ding, Yanbing","Wu, Xia","Long, Junke","Zhong, Yanjun","Li, Yiming","32234468"],"abstract":["In December 2019, the outbreak of the 2019 novel coronavirus disease (COVID-19) in China spread worldwide, becoming an emergency of major international concern. SARS-CoV-2 infection causes clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus. Human-to-human transmission has been described with incubation times between 2-14 days, facilitating its spread via droplets, contaminated hands or surfaces. Early diagnosis, quarantine, and supportive treatments are essential to cure patients. We therefore reviewed the literature on all available information about the epidemiology, diagnosis, isolation and treatments of COVID-19. Treatments, including antiviral agents, chloroquine and hydroxychloroquine, corticosteroids, antibodies, convalescent plasma transfusion and vaccines, will be discussed in this article. Additionally, registered trials about treatment were listed to develop approaches for the current urgent demand for therapy."],"journal":"Int J Antimicrob Agents","authors":["Zhai, Pan","Ding, Yanbing","Wu, Xia","Long, Junke","Zhong, Yanjun","Li, Yiming"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32234468","week":"202014|Mar 30 - Apr 05","doi":"10.1016/j.ijantimicag.2020.105955","keywords":["COVID-19","Clinical trials","Diagnosis","Isolation","Pandemic","Remdesivir"],"source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis","Treatment"],"weight":1,"e_drugs":["Chloroquine","Hydroxychloroquine"],"_version_":1663352135457177600,"score":60.510487},{"pmid":32124179,"title":"Clinical trials for the treatment of Coronavirus disease 2019 (COVID-19): A rapid response to urgent need.","text":["Clinical trials for the treatment of Coronavirus disease 2019 (COVID-19): A rapid response to urgent need.","Sci China Life Sci","Zhang, Tengyue","He, Yudi","Xu, Wenshuai","Ma, Aiping","Yang, Yanli","Xu, Kai-Feng","32124179"],"journal":"Sci China Life Sci","authors":["Zhang, Tengyue","He, Yudi","Xu, Wenshuai","Ma, Aiping","Yang, Yanli","Xu, Kai-Feng"],"date":"2020-03-04T11:00:00Z","year":2020,"_id":"32124179","week":"202010|Mar 02 - Mar 08","doi":"10.1007/s11427-020-1660-2","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1663352134296403968,"score":56.39794},{"pmid":32278362,"title":"Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed.","text":["Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed.","Lancet","Feldmann, Marc","Maini, Ravinder N","Woody, James N","Holgate, Stephen T","Winter, Gregory","Rowland, Matthew","Richards, Duncan","Hussell, Tracy","32278362"],"journal":"Lancet","authors":["Feldmann, Marc","Maini, Ravinder N","Woody, James N","Holgate, Stephen T","Winter, Gregory","Rowland, Matthew","Richards, Duncan","Hussell, Tracy"],"date":"2020-04-13T11:00:00Z","year":2020,"_id":"32278362","week":"202016|Apr 13 - Apr 19","doi":"10.1016/S0140-6736(20)30858-8","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1663890921986457600,"score":54.765186},{"pmid":32267301,"title":"Driving forces for COVID-19 clinical trials using chloroquine: the need to choose the right research questions and outcomes.","text":["Driving forces for COVID-19 clinical trials using chloroquine: the need to choose the right research questions and outcomes.","Rev Soc Bras Med Trop","Monteiro, Wuelton Marcelo","Brito-Sousa, Jose Diego","Baia-da-Silva, Djane","Melo, Gisely Cardoso de","Siqueira, Andre Machado","Val, Fernando","Daniel-Ribeiro, Claudio Tadeu","Guimaraes Lacerda, Marcus Vinicius","32267301"],"journal":"Rev Soc Bras Med Trop","authors":["Monteiro, Wuelton Marcelo","Brito-Sousa, Jose Diego","Baia-da-Silva, Djane","Melo, Gisely Cardoso de","Siqueira, Andre Machado","Val, Fernando","Daniel-Ribeiro, Claudio Tadeu","Guimaraes Lacerda, Marcus Vinicius"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32267301","week":"202015|Apr 06 - Apr 12","doi":"10.1590/0037-8682-0155-2020","source":"PubMed","topics":["Treatment"],"weight":1,"e_drugs":["Chloroquine"],"_version_":1663609715824787457,"score":48.556503},{"pmid":32279351,"title":"We urgently need guidelines for managing COVID-19 in children with comorbidities.","text":["We urgently need guidelines for managing COVID-19 in children with comorbidities.","I read with great interest the systematic review by Ludvigsson on the coronavirus disease 2019 (COVID-19) (1). The author needs to be complimented for a well-timed, rigorous and rapid synthesis of the evidence from the rather scant data available on how the virus affects children. The review, which focused on all papers published up to 19 March, drew important conclusions that have significant practical implications for those involved in providing acute care for children suffering from this disease.","Acta Paediatr","Dayal, Devi","32279351"],"abstract":["I read with great interest the systematic review by Ludvigsson on the coronavirus disease 2019 (COVID-19) (1). The author needs to be complimented for a well-timed, rigorous and rapid synthesis of the evidence from the rather scant data available on how the virus affects children. The review, which focused on all papers published up to 19 March, drew important conclusions that have significant practical implications for those involved in providing acute care for children suffering from this disease."],"journal":"Acta Paediatr","authors":["Dayal, Devi"],"date":"2020-04-13T11:00:00Z","year":2020,"_id":"32279351","week":"202016|Apr 13 - Apr 19","doi":"10.1111/apa.15304","source":"PubMed","topics":["Prevention","Diagnosis"],"weight":1,"_version_":1663890921981214721,"score":46.31674}]}